NCT04505254View on ClinicalTrials.gov

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Acalabrutinib

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER